Life-Threatening Thrombosis in Mice With Targeted Arg48-to-Cys Mutation of the Heparin-Binding Domain of Antithrombin
Mieke Dewerchin(Vlaams Instituut voor Biotechnologie), Jean‐Marc Herbert(Sanofi (France)), L. Millet(Sanofi (France)), Goedele Wallays(Hamilton General Hospital), Jeffrey I. Weitz(McMaster University Medical Centre), Paul Schaeffer(Universidad La Salle), Lieve Moons(Allen Institute for Brain Science), Désiré Collen(Ghent University), Maurice Petitou(Sanofi (France)), Jean-Pascal Hérault(Sanofi (France)), Peter Carmeliet(Khalifa University of Science and Technology)
Cited by 27
Related Papers
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
|Nature|1996|4.2k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
|Nature Medicine|2001|1.7k
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k